←back to thread

Weight-loss drug found to shrink muscle in mice, human cells

(www.ualberta.ca)
234 points Eumenes | 4 comments | 20 Nov 24 23:53 UTC | HN request time: 0s | source
Show context
jyscao ◴[21 Nov 24 00:46 UTC] No.42199859[source]▶
When Ozempic started making the rounds in the news with glowing reviews, my instincts told me there likely was some long term negative effective that wasn't immediately apparent yet.

If something sounds good too good to be true, it usually is.

replies(6): >>42200376 #>>42200403 #>>42201163 #>>42201420 #>>42201424 #>>42202235 #
1. monero-xmr ◴[21 Nov 24 02:17 UTC] No.42200403[source]▶
No one seems to remember Fen Phen or its stratospheric rise and fall https://en.m.wikipedia.org/wiki/Fenfluramine/phentermine
replies(2): >>42201246 #>>42201282 #
2. Someone1234 ◴[21 Nov 24 04:54 UTC] No.42201246[source]▶
No one who brings up Fen Phen seems to grasp how long both that and GLP-1s have been on the market. We're up to 4x Fen Phen's run already (5-years Vs. 20-years). GLP-1 Agonists aren't new, they've just been approved for additional usages.

So why, after 20-years, and millions of people haven't fen-phen-like side effects appeared?

3. MBCook ◴[21 Nov 24 05:00 UTC] No.42201282[source]▶
That was one of my first thoughts.

It’s perfectly possible for a new hot to have a severe side effect that won’t be noticed for quite a long time.

Semiglutide appears to have undergone final clinical trials in the US around 2017. Given it hasn’t been on the market terribly long and has only an exploded in popularity relatively recently it doesn’t seem like it would be that hard for it to have a serious side effect in a small portion of the population that hadn’t been detected before due to the limited number of people taking it, the amount of time it takes to manifest, or both.

Obviously it’s providing significant benefit that risk could easily be worth it. But as it gets marketed towards more and more people that won’t be true for all of them.

replies(1): >>42201367 #
4. cthalupa ◴[21 Nov 24 05:19 UTC] No.42201367[source]▶
Semaglutide is a 3rd generation GLP-1 agonist, though. We're 20 years in on GLP-1s at this point.